Last reviewed · How we verify
Autologous cord blood cell therapy
Autologous cord blood cell therapy is a Biologic drug developed by Neonatal Encephalopathy Consortium, Japan. It is currently in Phase 2 development for Treatment of neonatal encephalopathy.
Autologous cord blood cell therapy involves using a patient's own cord blood cells to stimulate healing and repair in damaged tissues.
Autologous cord blood cell therapy involves using a patient's own cord blood cells to stimulate healing and repair in damaged tissues. Used for Treatment of neonatal encephalopathy.
At a glance
| Generic name | Autologous cord blood cell therapy |
|---|---|
| Sponsor | Neonatal Encephalopathy Consortium, Japan |
| Modality | Biologic |
| Therapeutic area | Neonatology |
| Phase | Phase 2 |
Mechanism of action
This treatment works by introducing stem cells from the patient's own cord blood into the affected area, where they can differentiate into various cell types and promote tissue regeneration. The exact mechanisms of action are not fully understood, but it is thought to involve the release of growth factors and other signaling molecules that stimulate cellular repair and regeneration.
Approved indications
- Treatment of neonatal encephalopathy
Common side effects
- Fever
- Infection
- Bleeding
Key clinical trials
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease (PHASE1)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Extracellular Vesicles for the Treatment of Syringomyelia (PHASE1)
- Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors (EARLY_PHASE1)
- Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (PHASE2)
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (PHASE2)
- Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous cord blood cell therapy CI brief — competitive landscape report
- Autologous cord blood cell therapy updates RSS · CI watch RSS
- Neonatal Encephalopathy Consortium, Japan portfolio CI
Frequently asked questions about Autologous cord blood cell therapy
What is Autologous cord blood cell therapy?
How does Autologous cord blood cell therapy work?
What is Autologous cord blood cell therapy used for?
Who makes Autologous cord blood cell therapy?
What development phase is Autologous cord blood cell therapy in?
What are the side effects of Autologous cord blood cell therapy?
Related
- Manufacturer: Neonatal Encephalopathy Consortium, Japan — full pipeline
- Therapeutic area: All drugs in Neonatology
- Indication: Drugs for Treatment of neonatal encephalopathy
- Compare: Autologous cord blood cell therapy vs similar drugs
- Pricing: Autologous cord blood cell therapy cost, discount & access